Fosgonimeton, an experimental therapy Athira Pharma is developing to treat Alzheimer’s disease, was well-tolerated overall in a Phase 1 clinical trial that included Alzheimer’s patients as well as healthy volunteers. “These encouraging results showed a positive safety and tolerability profile of fosgonimeton across a wide dose range,” Hans Moebius, MD, PhD, Athira’s chief medical officer, said in a press release. The potential therapy is now in a fully enrolled Phase 2 trial in Alzheimer’s patients due…
You must be logged in to read/download the full post.
The post Fosgonimeton Shows Safety in Early Trial, Phase 3 Study Enrolling in US appeared first on BioNewsFeeds.